🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

When it comes to medicine development, success is achieved by our people – passionate experts working to combine their unique crafts with one purpose in mind – challenging the status quo to help the patients of tomorrow. Swipe to see what our employees have to say about the team.

In a world overflowing with data and noise, the most powerful tool we have is the timeless art of storytelling. Watch Kim Wix, Executive Director of Corporate Communications Daiichi Sankyo US, as she shares her unique craft of storytelling to evoke emotion & why choosing the

#NEWS: Daiichi Sankyo US has initiated the DESTINY-Gastric05 phase 3 trial in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) cancer, in collaboration with AstraZenecaUS. Click for more.

#NEWS: Today we announced topline results from the DESTINY-Breast09 phase 3 trial in certain patients with previously untreated HER2 positive metastatic breast cancer, in collaboration with AstraZenecaUS. Click the image to learn more. #mBC #HER2

#NEWS: Today we announced topline results from the DESTINY-Breast11 phase 3 trial in patients with high-risk #HER2 positive early-stage breast cancer, in collaboration with AstraZenecaUS. Click the image to learn more. #BreastCancer #NationalCancerResearchMonth #OncologyNews

#BREAKINGNEWS: Daiichi Sankyo US has initiated the IDeate-Esophageal01 phase 3 trial in certain patients with pretreated advanced or metastatic esophageal squamous cell carcinoma (#ESCC) in collaboration with Merck. Click the link for more information.

#ASCO25NEWS: Throughout ASCO, we will present more than 20 abstracts across our oncology portfolio, including two late-breaking oral presentations. Click to learn more about the specific presentations and follow us during #ASCO25 for more data updates: bit.ly/3ZtVSg8

Metastatic Breast Cancer is different. It is more complex than early-stage #BreastCancer, requiring alternative treatment plans. Learn about the nuances & how Daiichi Sankyo US is developing innovations that may change the treatment landscape for patients. Click now to read. #mBC

#BREAKINGNEWS: Today at a late breaking oral presentation at #ASCO25 positive results from the DESTINY-Gastric04 phase 3 trial were presented in collaboration with AstraZenecaUS. Click the image to learn more. #GastricCancer #HER2Positive

#NEWS: Results from the TROPION-Lung02 & TROPION-Lung04 phase 1b trials & NeoCOAST-2 phase 2 trial showing promising tumor responses in patients with early and advanced #NSCLC were presented today at #ASCO25, in collaboration with AstraZenecaUS. Click the image to learn more.

#BREAKINGNEWS: Today during a special late breaking oral presentation at #ASCO25, results from the DESTINY-Breast09 phase 3 trial were presented in collaboration with AstraZenecaUS. Click the image to learn more. #mBC #HER2Positive

Register now for the BioPharma Dive & @pharmavoice virtual event this Thursday featuring Daiichi Sankyo US CEO, Ken Keller, as he discusses the ins and outs of “Building a blockbuster ADC franchise”. Register here: bit.ly/43EKRdd

#BREAKINGNEWS: Daiichi Sankyo US has initiated the DESTINY-Endometrial01 phase 3 trial in patients with previously untreated HER2 expressing advanced endometrial cancer, in collaboration with AstraZenecaUS. Click the image for more information. #EndometrialCancer

#BREAKINGNEWS: Daiichi Sankyo US has initiated the IDeate-Prostate01 phase 3 trial in certain patients with pretreated metastatic castration-resistant prostate cancer in collaboration with Merck. Click the link for more information: bit.ly/3G7ERSx

#BreakingNews: Today the FDA approved our TROP2 directed DXd #ADC for previously treated adult patients with locally advanced or metastatic #EGFR-mutated #NSCLC in collaboration w/ AstraZenecaUS. Click the image to learn more.

There is more to metastatic breast cancer than the science. Patricia Judson, M.D., Vice President U.S. Medical Affairs, discusses the importance of recognizing the different tone and unique needs of patients with #mBC. Click now to read the full story. #MetastaticBreastCancer

Behind every medicine is a story. At Daiichi Sankyo, our experts combine precision and purpose to drive innovation. Discover how their unique crafts help transform science into medicines for the patients of today and tomorrow. 🔗 bit.ly/3TOL88S

#BREAKINGNEWS: Today we announced the publication of final long-term efficacy and safety results from the open-label extension of the ENLIVEN phase 3 trial of our medicine in patients with tenosynovial giant cell tumor. Click the image to learn more. #TGCT

#NEWS: The FDA granted Breakthrough Therapy Designation for our HER2 directed #ADC, as part of a combination regimen, for the first-line treatment of adult patients w/ HER2 positive #mBC in collaboration w/ AstraZenecaUS. This is the 13th BTD across our oncology portfolio.

Ray Bedeaux turns complexity into impact. His craft, "Synthesis," ensures the critical medicines we create reach patients who need them most. Share your unique craft below and how it is shaping the future. Read our Company Brochure to learn how we are making an impact: